| In ZINC since | Heavy atoms | Benign functionality |
|---|---|---|
| July 24th, 2004 | 31 | No |
Popular Name: Glipizide Glipizide
Find On: PubMed — Wikipedia — Google
CAS Numbers: 29094-61-9 , 29094-66-4 , [29094-61-9]
1-Cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)urea
1-Cyclohexyl-3-{4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonyl}urea
29094-61-9; CPD000058455; GLIPIZIDE; SAM002564210
29094-61-9; D00335; Glipizide (USP/INN); Glucotrol (TN)
29094-61-9; Glipizide; Prestwick_242
CPD000058455; Glipizide; SAM002564210
Glipizida [INN-Spanish];Glipizidum [INN-Latin];Glydiazinamide
glipizida; glipizide; glipizidum
Glipizide Extended-Release Tablets
GLIPIZIDE; GLIPIZIDE AND METFORMIN HYDROCHLORIDE; LS-187967; METFORMIN HYDROCHLORIDE
Glucotrol XL, Glucotrol, Glipizide
N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-5-methylpyrazine-2-carboxamide
N-(4-(beta-(5-Methylpyrazine-2-carboxamido)ethyl)benzenesulphonyl)-N'-cyclohexylurea
N-(4-(N-(cyclohexylcarbamoyl)sulfamoyl)phenethyl)-5-methylpyrazine-2-carboxamide
N-(4-[N-(cyclohexylcarbamoyl)sulfamoyl]phenethyl)-5-methylpyrazine-2-carboxamide
N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-5-methylpyrazine-2-carboxamide
N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide
Pyrazinecarboxamide, N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-5-methyl-
Pyrazinecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl-
Urea, 1-cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)-
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | 1.94 | 1.45 | -65.23 | 2 | 9 | -1 | 136 | 444.537 | 8 | ↓ |
| Ref Reference (pH 7) | 1.94 | 0.9 | -22.02 | 3 | 9 | 0 | 134 | 445.545 | 8 | ↓ |
| Lo Low (pH 4.5-6) | 2.31 | 3.39 | -20.04 | 3 | 9 | 0 | 130 | 445.545 | 7 | ↓ |
| Note Type | Comments | Provided By |
|---|---|---|
| ALOGPS_SOLUBILITY | 1.64e-02 g/l | DrugBank-approved |
| MP | 206 | TCI |
| Indications | antidiabetic | KeyOrganics Bioactives |
| biological_use | Antidiabetic drug | IBScreen Bioactives |
| biological_use | Antihyperglycaemic agent | IBScreen Bioactives IBScreen Bioactives |
| Therapy | ATP-dependent K+ channel blocker | SMDC Iconix |
| PUBCHEM_SUBSTANCE_COMMENT | NCC_SAMPLE_SUPPLIER : LightBiologicals; NCC_SUPPLIER_STRUCTURE_ID : G-0443; NCC_SUPPLIER_SAMPLE_COMMENTS : WHITE POWDER | NIH Clinical Collection via PubChem |
| Target | Others | Selleck Chemicals |
| mechanism | Potassium channels | ZereneX Building Blocks |
| mechanism | Potassium channels (KATP) blocker | IBScreen Bioactives |
| S phrase | S24/25: Avoid contact with skin and eyes. | Acros Organics |
| PUBCHEM_SUBSTANCE_COMMENT | SAMPLE_SUPPLIER: LightBiologicals; SUPPLIER_STRUCTURE_ID: G-0443; SUPPLIER_COMMENTS: WHITE POWDER | NIH Clinical Collection via PubChem |
| Indications | type II diabetes | KeyOrganics Bioactives |
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| ABCC9-1-E | Sulfonylurea Receptor 2 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 8 | 0.37 | Binding ≤ 10μM |
| IRK11-1-E | Potassium Channel, Inwardly Rectifying, Subfamily J, Member 11 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 8 | 0.37 | Binding ≤ 10μM |
| IRK8-1-E | Potassium Channel, Inwardly Rectifying, Subfamily J, Member 8 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 8 | 0.37 | Binding ≤ 10μM |
| KCND3-1-E | Voltage-gated Potassium Channel Subunit Kv4.3 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 8 | 0.37 | Binding ≤ 10μM |
| CP3A4-2-E | Cytochrome P450 3A4 (cluster #2 Of 4), Eukaryotic | Eukaryotes | 7447 | 0.23 | ADME/T ≤ 10μM |
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| IRK11_RAT | P70673 | Potassium Channel, Inwardly Rectifying, Subfamily J, Member 11, Rat | 8.2 | 0.37 | Binding ≤ 1μM |
| IRK8_RAT | Q63664 | Potassium Channel, Inwardly Rectifying, Subfamily J, Member 8, Rat | 8.2 | 0.37 | Binding ≤ 1μM |
| ABCC9_RAT | Q63563 | Sulfonylurea Receptor 2, Rat | 8.2 | 0.37 | Binding ≤ 1μM |
| KCND3_HUMAN | Q9UK17 | Voltage-gated Potassium Channel Subunit Kv4.3, Human | 8.2 | 0.37 | Binding ≤ 1μM |
| IRK11_RAT | P70673 | Potassium Channel, Inwardly Rectifying, Subfamily J, Member 11, Rat | 8.2 | 0.37 | Binding ≤ 10μM |
| IRK8_RAT | Q63664 | Potassium Channel, Inwardly Rectifying, Subfamily J, Member 8, Rat | 8.2 | 0.37 | Binding ≤ 10μM |
| ABCC9_RAT | Q63563 | Sulfonylurea Receptor 2, Rat | 8.2 | 0.37 | Binding ≤ 10μM |
| KCND3_HUMAN | Q9UK17 | Voltage-gated Potassium Channel Subunit Kv4.3, Human | 8.2 | 0.37 | Binding ≤ 10μM |
| CP3A4_HUMAN | P08684 | Cytochrome P450 3A4, Human | 7447.31974 | 0.23 | ADME/T ≤ 10μM |
| Description | Species |
|---|---|
| Aflatoxin activation and detoxification | |
| ATP sensitive Potassium channels | |
| Regulation of insulin secretion | |
| Voltage gated Potassium channels | |
| Xenobiotics |
No pre-computed analogs available. Try a structural similarity search.